This R848-loaded rGOQD was further surface conjugated with aPD-L1 to prepare intravenous injectable rGOQD/R8/aPDL1 nanoparticle, which can target the PD-L1 on the glioma cell surface for sustained release of the immunoadjuvant (Figure 1). This evidence concerns the gene CD274 and central nervous system cancer.